

USA, ⁸Perth Children's Hospital, Nedlands, WA, Australia, ⁹Fundacion para Lucha contra las Enfermedades Neurológicas de Infantes, Buenos Aires, Argentina, ¹⁰Children's Hospital Colorado, Aurora, CO, USA, ¹¹Children's Cancer Hospital Egypt, Cairo, Egypt, ¹²Dayton Children's Hospital, Dayton, OH, USA, ¹³Stanford Children's Health, Palo Alto, CA, USA, ¹⁴Hospital de Niños Ricardo Gutiérrez, Gallo, Argentina, ¹⁵Penn State Health Children's Hospital, Hershey, PA, USA, ¹⁶Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA, ¹⁷University of Florida, Gainesville, FL, USA, ¹⁸The Royal Children's Hospital, Parkville, Australia, ¹⁹Queensland Children's Hospital, South Brisbane, Australia, ²⁰Children's National, Washington, DC, USA, ²¹University of Michigan, Ann Arbor, MI, USA, ²²Seattle Children's, Seattle, WA, USA, ²³Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²⁴Children's Hospital of Philadelphia, Philadelphia, PA, USA, ²⁵CHU Saint Justine, Montreal, Canada, ²⁶Nemours Children's Health System, Jacksonville, FL, USA, ²⁷St. Jude Children's Research Hospital, Memphis, TN, USA, ²⁸Starship Children's Health, Auckland, New Zealand, ²⁹University of Kentucky College of Medicine, Lexington, KY, USA, ³⁰Sydney Children's Hospital, Sydney, Australia

INTRODUCTION: The role of diagnostic biopsy in diffuse intrinsic pontine glioma (DIPG) remains in question. Distinguishing radiographically between DIPG and other pontine tumors with more favorable prognosis and different therapy is critically important. **METHODS:** Cases submitted to the International DIPG registry with histopathologic data were analyzed. Central imaging review was performed by two neuro-radiologists; all cases with imaging features or histopathology suggestive of alternative diagnoses were re-reviewed. Imaging features suggestive of alternative diagnoses included non-pontine origin, <50% pontine involvement (without typical DIPG pattern on follow-up), focally exophytic morphology, sharply-defined margins, or marked diffusion restriction throughout. **RESULTS:** Among 297 patients with pathology from biopsy and/or autopsy available, 27 (9%) had histologic diagnoses not consistent with DIPG, commonly embryonal tumors (n=9) and pilocytic astrocytomas (n=11). 163 patients had diagnostic MRI available for central neuroimaging review. Among 81 patients classified as characteristic of DIPG, 80 (99%) had histopathology consistent with DIPG (diffuse midline glioma, H3K27M-mutant, glioblastoma, anaplastic astrocytoma, diffuse astrocytoma). Among 63 patients classified as likely DIPG, but with unusual imaging features, 59 (94%) had histopathology consistent with DIPG. 19 patients had imaging features suggestive of another diagnosis, including 13 with non-pontine tumor origin; the remaining 6 all had histopathology not consistent with DIPG. Association between central imaging review and histopathology was significant (p<0.001). **CONCLUSIONS:** The important role and accuracy of central neuroimaging review in diagnosing or excluding DIPG is demonstrated. In patients with pontine tumors for which DIPG is felt unlikely radiographically, biopsy may be considered to guide diagnosis and treatment.

DIPG-47. HISTONE MUTATIONS ENHANCE RAS MEDIATED ERK5 GROWTH SIGNALING IN DIFFUSE MIDLINE GLIOMAS

Ann-Catherine Stanton¹, Robert Koncar¹, Brian Golbourn¹, Brittany Dey¹, Nishant Agrawal¹, Stephen Mack², Ian Pollack¹, and Sameer Agnihotri¹; ¹Department of Neurological Surgery, Children's Hospital, University of Pittsburgh, Pittsburgh, PA, USA, ²Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA

Diffuse midline gliomas (DMGs) are incurable brain tumors with an aggressive onset. Apart from irradiation, there are currently no effective therapies available for patients with DMG, who have a median survival time of less than one year. Most DMG cells harbor mutations in genes encoding histone H3 (H3K27M) proteins, resulting in a global reduction of H3K27 trimethylation and activation of oncogenic signaling pathways. Here we show that the H3K27M mutations contribute to RAS pathway signaling, which is augmented by additional RAS activators including PDGFRA. H3K27M mutation led to increased expression of receptor tyrosine kinases (RTK). A RAS pathway functional screen identified ERK5, but not ERK1/2, as a RAS pathway effector important for DMG growth. Suppression of ERK5 decreased DMG cell proliferation and induced apoptosis *in vitro* and *in vivo*. In addition, depletion or inhibition of ERK5 significantly increased survival of mice intracranially engrafted with DMG cells. Mechanistically, ERK5 directly stabilized the proto-oncogene MYC at the protein level. Additionally, persistent ERK5 depletion does not result in complete growth inhibition and therefore we set out to determine potential adaptation or resistance mechanisms in response to ERK5 loss. Using RNA-sequencing and Immunoprecipitation (IP) mass spectrometry (IP-MS), we have identified several positive and negative feedbacks involved in ERK5 that are also targetable. These findings identify the H3K27M mutation as an enhancer of RAS activation in DMG with ERK5 and ERK5 regulated networks immediately actionable pathways.

DIPG-49. BRAINSTEM AND PONTINE VOLUMETRIC ANALYSIS AS A SURROGATE MEASURE OF LOCAL DISEASE CONTROL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Evan D. Bander^{1,2}, Morgan E. Freret², Eva Wembacher-Schroeder³, Suzanne L. Wolden², and Mark M. Souweidane¹; ¹Weill Cornell Medical

College/NY Presbyterian Hospital, New York, NY, USA, ²Memorial Sloan Kettering Cancer Center, New York, NY, USA, ³Brainlab AG, Munich, Germany

INTRODUCTION: Response-assessment in pediatric neuro-oncology (RAPNO) criteria designed to describe treatment outcomes are poorly implemented in diffuse intrinsic pontine glioma (DIPG), due to inter-observer variability in measurement of tumor volume, lack of tumor enhancement, and undefined relationships between radiographic parameters and survival. Given these issues, this study assessed whether anatomically defined brainstem and pontine volumes can serve as surrogate measures of local disease burden and response to therapy in DIPG. **METHODS:** Thirty-two consecutive patients with newly diagnosed DIPG were treated with standard definitive radiation therapy (RT) between 2010 and 2016 at a single institution. MRI brain scans throughout treatment course were analyzed using iPlan® Flow software (Brainlab AG, Munich, Germany). Semi-automated 3D measurements of the brainstem and pons were calculated using a built-in knowledge-based segmentation approach and manually adjusted. **RESULTS:** Mean age at diagnosis was 6.5+/-0.5 years (range 2-12 years). Median follow up time was 317 days. Average brainstem volume at diagnosis (Vdiag) was 52.7+/-2.1mL with subsequent decrease at first post-RT MRI to 41.4+/-2.0mL (p < 0.0001). By time of last follow up, brainstem volume increased to 51.9+/-3.3, no longer significantly different as compared to Vdiag (p=0.61). The same relationships were found for pontine volume. **CONCLUSIONS:** Volumetric changes in the brainstem and pons occur in response to treatment and correlate with local disease burden and response to therapy. This surrogate may be a useful standardized measure in ongoing and future trials involving localized delivery of therapeutics in DIPG that require evaluation of local-regional disease control in addition to survival.

DIPG-50. A NOVEL ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODEL OF RADIATION-INDUCED GLIOMA

Jacqueline Whitehouse^{1,2}, Meegan Howlett^{1,2}, Jason Stanley^{1,2}, Hilary Hii¹, Santosh Valvi³, Christine White⁴, Chelsea Mayoh^{5,6}, Marie Wong^{5,6}, Brooke Strowger¹, Jason Dyke⁷, Mark Cowley^{5,6}, Nicholas Gottardo^{1,3}, Raelene Endersby^{1,2}, ¹Telethon Kids Institute, Perth, WA, Australia, ²University of Western Australia, Perth, WA, Australia, ³Perth Children's Hospital, Perth, WA, Australia, ⁴Hudson Institute of Medical Research, Melbourne, VIC, Australia, ⁵Children's Cancer Institute, Sydney, NSW, Australia, ⁶University of New South Wales, Sydney, NSW, Australia, ⁷Royal Perth Hospital, Perth, WA, Australia

Diffuse midline glioma (DMG) can arise as a primary tumour but also as a consequence of radiation therapy (RT) in survivors of other paediatric brain tumours. Radiation-associated gliomas are molecularly distinct from primary gliomas and have poorer overall survival. We report a case of radiation-associated DMG following treatment for medulloblastoma, and the development of a matched patient-derived xenograft (PDX) model. A four-year-old boy diagnosed with medulloblastoma was treated with surgical resection, RT and chemotherapy (COG:CCG-99701-Arm B). Eleven years post-diagnosis, the patient relapsed with radiation-associated DMG, participated in a Phase I clinical trial (COG:ACNS0927), and passed away eight months later. Tumour tissue collected at autopsy was intracranially implanted into immunodeficient mice and serially transplanted *in vivo*. Immunohistochemistry demonstrated both the primary DMG and PDXs expressed PDGFR-alpha and PTEN, were H3K27me3-positive, and had undetectable levels of p53. Sequencing revealed an activating mutation in PI3-kinase (H1047L) and variants of unknown significance in *GRK4*, *FLG*, *BAZ2A*, and *CRTC3*. DNA methylation array of the PDX demonstrated 1p loss, which is not typically associated with primary DMG, and broad deletion within 9p including *CDKN2A/B*, *MTAP* and multiple interferon genes. The methylation profile did not significantly classify with other tumours in the Molecular Neuropathology database (molecularneuropathology.org/mmp). We describe the first reported PDX model of radiation-associated DMG following medulloblastoma, which recapitulates the patient disease and is molecularly distinct from primary DMG. Interrogation of this model through RNA and whole genome sequencing presents a valuable opportunity to better understand and identify novel therapeutic vulnerabilities against this currently incurable disease.

DIPG-51. ACVR1 MUTATIONS PROMOTE TUMOR GROWTH IN MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA

Jennifer Ocasio Adorno¹, Laura Hover¹, Chen He¹, Xiaoyan Zhu¹, David Goldhamer², Angel Carcaboso^{3,4}, Sridevi Yadavilli⁵, Javad Nazarian^{5,6}, and Suzanne Baker¹; ¹St. Jude Children's Research Hospital, Memphis, TN, USA, ²University of Connecticut, Storrs, CT, USA, ³Institut de Recerca Sant Joan de Deu, Barcelona, Spain, ⁴Hospital Sant Joan de Deu, Barcelona, Spain, ⁵Children's National Health System, Washington DC, USA, ⁶George Washington University, Washington DC, USA

Mutations in the gene encoding activin A receptor type 1 (*ACVR1*) are found in approximately 25% of diffuse intrinsic pontine gliomas